| Drug | Class | Brand / Formulation Notes |
| Clonidine | Central α₂ agonist | Kapvay® ER suspension (0.1 mg/mL); compounded immediate-release suspension. |
| Hydralazine | Direct vasodilator | No commercial liquid; compounded suspension (stable). |
| Lisinopril | ACE Inhibitor | Commercial oral solution 1 mg/mL (Qbrelis®). |
| Captopril | ACE Inhibitor | Commercial oral solution 1 mg/mL (Capoten®). |
| Enalapril | ACE Inhibitor | Commercial oral solution (Epaned® 1 mg/mL). |
| Terazosin | α₁ Blocker | No commercial liquid; compounded. |
| Prazosin | α₁ Blocker | Compounded suspension. |
| Methyldopa | Central α₂ agonist | Compounded suspension (used in pregnancy). |
| Propranolol | Beta-blocker | Commercial oral solution 20 mg/5 mL, 40 mg/5 mL (Hemangeol® for infantile hemangioma; off-label for HTN). |
| Metoprolol Tartrate | Beta-blocker | Compounded suspension. |
| Furosemide | Loop Diuretic | Commercial oral solution 10 mg/mL. |
| Spironolactone | MRA | Compounded suspension. |
Compounding
Most pharmacies can compound stable suspensions from tablets/capsules (crushing not recommended for ER/XR). Verify stability, dosing accuracy, and insurance coverage.
Clinical Considerations
- Bioavailability may differ slightly from tablets; monitor response.
- Shake well before each dose.
- Enteral tube: flush before/after; hold feeds if interaction risk (e.g., binding).
- Cost: Compounded liquids often more expensive; check formulary.
Hypertension - Related Articles